Macquarie Group

One of the biggest IPOs in London this year was revealed on Monday when Arqiva, the UK’s largest operator of TV and radio broadcast towers, launched an IPO with a projected valuation of about £5.5bn.

Empark, Vallourec and Dufry met strong demand for their new high yield bonds this week as investors opened their deep pockets.

Macquarie Capital has appointed Justin Ocampo as a managing director and the head of its Philippines office.

Macquarie has hired Ric Deverell as chief economist and head of macro research.

Two UK corporates completed successful equity capital markets transactions in the midst of the summer lull this week, providing investors with a small amount of supply.

Shares in Wilmcote Holdings, the UK specialty chemicals investment company, closed 10.4% higher on Thursday after they began trading on London’s Alternative Investment Market.

Celltrion Healthcare has bagged W1tr ($886.3m) after pricing its IPO at the top of the initial marketing range, according to a banker familiar with the matter.

Celltrion Healthcare is on track to raise W1tr ($882.4m) as it eyes the top of guidance for its IPO, taking advantage of strong demand from international long-only funds, according to a source close to the deal.

Roadshows have begun for the IPO of Celltrion Healthcare, the South Korean marketing affiliate of Celltrion, in a deal that can reach W1.008tr ($897m) if priced at the top of the range.

International schools operator Nord Anglia has tightened pricing and accelerated the deadline on its $1.22bn-equivalent euro term loan, while up to six leveraged loans are due to close syndication at the end of the week.

Misys has tinkered with the $5.35bn-equivalent loan package backing its acquisition of Canadian competitor D+H, with a banker on the deal saying the basis swap between dollars and euros was especially attractive to the issuer.

Misys, the UK financial software firm, held bank meetings on Tuesday in London for a €1bn term loan to back its $3.6bn-equivalent acquisition of D+H, a Canadian competitor, following sponsor Vista Equity Partners’ failed IPO of the UK firm last year.